Key Takeaways:
- A recent study published in the Veterinary Immunology and Immunopathology journal has demonstrated the effectiveness of Tonisity Px, a product by Tonisity International Limited, in combating Porcine Epidemic Diarrhea Virus (PEDV).
- This marks the first reported use of a commercially available swine feed supplement to show a beneficial impact on PEDV.
- The product, designed as a liquid supplement for swine, notably reduced virus shedding in infected piglets and enhanced their immune response and tissue recovery.
- The study provides a scientific basis for the potential application of Tonisity Px in improving animal health in the face of PEDV infections.
Introduction to the Study
Tonisity International Limited, an Ireland-based animal health and nutrition company, recently highlighted the results of a study involving their flagship product, Tonisity Px. This peer-reviewed article, appearing in the Veterinary Immunology and Immunopathology journal, presented new findings on the efficacy of this swine feed supplement against the Porcine Epidemic Diarrhea Virus (PEDV).
Study Details and Methodology
The research centered on administering Tonisity Px to 14-day-old piglets diagnosed with PEDV. Over a 21-day observation period, researchers evaluated indicators such as intestinal integrity, immune response, tissue repair, and virus shedding. According to the study, piglets receiving Tonisity Px experienced reduced PEDV shedding, particularly on days 5 and 14 post-infection, and completely cleared the virus by day 21.
Comparative Results and Implications
Compared to the control group, which continued to shed the virus throughout the study period, the Tonisity Px-treated piglets showed enhanced immune responses and accelerated tissue repair. “The results indicate a significant improvement in the treated piglets, not only in terms of reduced viral load but also in their overall intestinal health,” noted Dr. Ava Firth, Director of Research and Development at Tonisity.
Commentary from Experts
Dr. Stefan Buzoianu, Senior Scientist at Tonisity, commented on the scientific foundation of the study, stating, “This study confirms the physiological and immunological basis upon which Tonisity Px operates. It’s a pioneering step in identifying viable interventions against PEDV.” He also highlighted the introduction of a new set of biomarkers that help in understanding the immune dynamics at the intestinal level in live pigs suffering from PEDV infections.
Global Impact and Market Reach
Tonisity Px is registered across multiple continents, including Asia, Europe, South America, North America, Australia, and Africa. With over 65 million animals having used their products, Tonisity’s findings underline the potential for broader applications in improving animal health and managing disease. Dr. Firth added, “The success of Tonisity Px in these trials reflects our commitment to providing scientifically validated solutions to the agricultural sector.”
Read the complete study here.
Tonisity International Latest News
Gains Health Canada Approval to Enter Canadian Swine Market (2024/04/30)
Tonisity International has received approval from Health Canada to import and distribute Tonisity Px and PxW products in Canada. These products target swine production challenges such as improving piglet survival rates and optimizing growth. The patented isotonic protein drink, Tonisity Px, enhances nutrient absorption and overall health in piglets, leading to higher weight gains, reduced mortality, and a decreased need for medications. Tonisity is committed to research, as evidenced by nearly 235 swine trials conducted globally, proving the efficacy of its products.
Photo by Amber Kipp on Unsplash
